Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The REVERSE Study: Rapamycin and Prolon Diet for Reverse Aging
NCT07354620Phase 1Active, not recruiting
- Sponsor
- The Christ Hospital
- Start
- Feb 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sirolimus in aging (3 arms), sponsored by The Christ Hospital. Primary endpoint: Change in Biological Age at 24 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
aging
Beyond the preview
Go deeper on NCT07354620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07354620.